New cytotoxic agents and schedules for advanced breast cancer. Semin Oncol. 2001 Aug; 28(4):344-58.
New cytotoxic agents and schedules for advanced breast cancer.
Meyerhardt JA, Heseltine D, Campos H, Holmes MD, Willett WC, Winer EP, Enzinger PC, Bunnell CA, Kulke MH, Fuchs CS
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8453-60.
Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy.
Valero MG, Mallory MA, Losk K, Tukenmez M, Hwang J, Camuso K, Bunnell C, King T, Golshan M
Surgeon Variability and Factors Predicting for Reoperation Following Breast-Conserving Surgery. Ann Surg Oncol. 2018 Sep; 25(9):2573-2578.
Surgeon Variability and Factors Predicting for Reoperation Following Breast-Conserving Surgery.
Bunnell CA, Weingart SN, Swanson S, Mamon HJ, Shulman LN
Models of multidisciplinary cancer care: physician and patient perceptions in a comprehensive cancer center. J Oncol Pract. 2010 Nov; 6(6):283-8.
Models of multidisciplinary cancer care: physician and patient perceptions in a comprehensive cancer center.
Integrating value assessment into discussions about the price of cancer drugs. Mayo Clin Proc. 2012 Oct; 87(10):932-4.
Integrating value assessment into discussions about the price of cancer drugs.
Vahdat LT, Thomas ES, Roché HH, Hortobagyi GN, Sparano JA, Yelle L, Fornier MN, Martín M, Bunnell CA, Mukhopadhyay P, Peck RA, Perez EA
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Support Care Cancer. 2012 Nov; 20(11):2661-8.
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.
Natsuhara KH, Losk K, King TA, Lin NU, Camuso K, Golshan M, Pochebit S, Brock JE, Bunnell CA, Freedman RA
Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria. Oncologist. 2019 05; 24(5):595-602.
Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
Campos SM, Berlin ST, Parker LM, Chen WY, Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, Krasner CN
International journal of clinical oncology
Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Int J Clin Oncol. 2010 Aug; 15(4):390-8.
Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer.
Bunnell C, Vahdat L, Schwartzberg L, Gralow J, Klimovsky J, Poulart V, Peck R, Thomas E
Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer. 2008 Jun; 8(3):234-41.
Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
Barginear M, Dueck AC, Allred JB, Bunnell C, Cohen HJ, Freedman RA, Hurria A, Kimmick G, Le-Rademacher JG, Lichtman S, Muss HB, Shulman LN, Copur MS, Biggs D, Ramaswamy B, Lafky JM, Jatoi A
Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101. Oncologist. 2019 05; 24(5):617-623.
Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101.
Whorms DS, Giess CS, Golshan M, Freedman RA, Bunnell CA, Alper EC, Losk K, Khorasani R
Journal of the American College of Radiology : JACR
Clinical Impact of Second Opinion Radiology Consultation for Patients With Breast Cancer. J Am Coll Radiol. 2019 Jun; 16(6):814-823.
Clinical Impact of Second Opinion Radiology Consultation for Patients With Breast Cancer.
Lecturer on Obstetrics, Gynecology and Reproductive Biology, Part-time
Jerome and Nancy Kohlberg Professor of Medicine
Tolaney SM, Najita J, Sperinde J, Huang W, Chen WY, Savoie J, Fornier M, Winer EP, Bunnell C, Krop IE
Annals of oncology : official journal of the European Society for Medical Oncology
A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol. 2013 Jul; 24(7):1841-1847.
A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer.
Jackman DM, Hamilton J, Foster E, Bunnell CA, Culot L, Tremonti C, Jacobson JO
Lessons from the front: designing and implementing clinical pathways by and for clinicians. Am J Manag Care. 2020 02; 26(2 Spec No.):SP57-SP59.
Lessons from the front: designing and implementing clinical pathways by and for clinicians.
Lynce F, Williams JT, Regan MM, Bunnell CA, Freedman RA, Tolaney SM, Chen WY, Mayer EL, Partridge AH, Winer EP, Overmoyer B
Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. Cancer Chemother Pharmacol. 2021 05; 87(5):673-679.
Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.
Jackman DM, Foster E, Hamilton JM, Tremonti C, Bunnell CA, Stuver SO, Jacobson JO
American journal of medical quality : the official journal of the American College of Medical Quality
Early Findings on the Use of Clinical Pathways for Management of Unwarranted Variation in Cancer Care. Am J Med Qual. 2022 Mar-Apr 01; 37(2):103-110.
Early Findings on the Use of Clinical Pathways for Management of Unwarranted Variation in Cancer Care.
Trapani D, Jin Q, Block CC, Freedman RA, Lin NU, Tarantino P, Mittendorf EA, King TA, Lester SC, Brock JE, Tayob N, Bunnell CA, Tolaney SM, Burstein HJ
Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and Reimbursement. JCO Oncol Pract. 2023 08; 19(8):560-570.
Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and Reimbursement.
Teaching Associate in Obstetrics, Gynecology and Reproductive Biology
Little JS, Coughlin C, Hsieh C, Lanza M, Huang WY, Kumar A, Dandawate T, Tucker R, Gable P, Vazquez Deida AA, Moulton-Meissner H, Stevens V, McAllister G, Ewing T, Diaz M, Glowicz J, Winkler ML, Pecora N, Kubiak DW, Pearson JC, Luskin MR, Sherman AC, Woolley AE, Brandeburg C, Bolstorff B, McHale E, Fortes E, Doucette M, Smole S, Bunnell C, Gross A, Platt D, Desai S, Fiumara K, Issa NC, Baden LR, Rhee C, Klompas M, Baker MA
Neuroinvasive Bacillus cereus Infection in Immunocompromised Hosts: Epidemiologic Investigation of 5 Patients With Acute Myeloid Leukemia. Open Forum Infect Dis. 2024 Mar; 11(3):ofae048.
Neuroinvasive Bacillus cereus Infection in Immunocompromised Hosts: Epidemiologic Investigation of 5 Patients With Acute Myeloid Leukemia.
Jacobson JO, Rompelman G, Chen A, Morrison-Ma S, Murray L, Ferzoco M, Bunnell C, Wagner AJ, Roberts D, Chan J, Block C, Rubinson D
Design and Implementation of an Opt-Out, End-to-End, Preemptive DPYD Testing Program for Patients Planned for a Systemic Fluoropyrimidine. JCO Oncol Pract. 2024 Aug; 20(8):1115-1122.
Design and Implementation of an Opt-Out, End-to-End, Preemptive DPYD Testing Program for Patients Planned for a Systemic Fluoropyrimidine.
Bunnell CA, Gross AH, Weingart SN, Kalfin MJ, Partridge A, Lane S, Burstein HJ, Fine B, Hilton NA, Sullivan C, Hagemeister EE, Kelly AE, Colicchio L, Szabatura AH, Winer EP, Salisbury M, Mann S
High performance teamwork training and systems redesign in outpatient oncology. BMJ Qual Saf. 2013 May; 22(5):405-13.
High performance teamwork training and systems redesign in outpatient oncology.
Sato K, Tamaki K, Bunnell CA, Hiraide H, Mochizuki H
Gan to kagaku ryoho. Cancer & chemotherapy
[Advances in sentinel node biopsy for breast cancer]. Gan To Kagaku Ryoho. 2004 Oct; 31(10):1601-7.
[Advances in sentinel node biopsy for breast cancer].
Continued Promise and Possibility of Prospective Payment System Exemption: An Investment in the Future of Cancer Care Innovation. JCO Oncol Pract. 2025 Jul; 21(7):918-920.
Continued Promise and Possibility of Prospective Payment System Exemption: An Investment in the Future of Cancer Care Innovation.
Bunnell CA, Losk K, Kadish S, Lin N, Hirshfield-Bartek J, Cutone L, Camuso K, Golshan M, Weingart S
Journal of the National Comprehensive Cancer Network : JNCCN
Measuring opportunities to improve timeliness of breast cancer care at Dana-Farber/Brigham and Women's Cancer Center. J Natl Compr Canc Netw. 2014 Feb; 12 Suppl 1:S5-9.
Measuring opportunities to improve timeliness of breast cancer care at Dana-Farber/Brigham and Women's Cancer Center.
Golshan M, Losk K, Kadish S, Lin NU, Hirshfield-Bartek J, Cutone L, Sagara Y, Aydogan F, Camuso K, Weingart SN, Bunnell C
Understanding process-of-care delays in surgical treatment of breast cancer at a comprehensive cancer center. Breast Cancer Res Treat. 2014 Nov; 148(1):125-33.
Understanding process-of-care delays in surgical treatment of breast cancer at a comprehensive cancer center.
Greenblatt MB, Torre M, Means J, Tanasijevic M, Vitale Pedulla L, Bunnell CA, Conrad MJ, Jarolim P
Use of potassium concentrations as a quality-of-service metric for phlebotomists detects systematic preanalytical biases and facilitates their correction. Clin Chem. 2014 Nov; 60(11):1453-5.
Use of potassium concentrations as a quality-of-service metric for phlebotomists detects systematic preanalytical biases and facilitates their correction.
Mallory MA, Losk K, Lin NU, Sagara Y, Birdwell RL, Cutone L, Camuso K, Bunnell C, Aydogan F, Golshan M
The Influence of Radiology Image Consultation in the Surgical Management of Breast Cancer Patients. Ann Surg Oncol. 2015 Oct; 22(10):3383-8.
The Influence of Radiology Image Consultation in the Surgical Management of Breast Cancer Patients.
Golshan M, Losk K, Mallory MA, Camuso K, Troyan S, Lin NU, Kadish S, Bunnell CA
Variation in Additional Breast Imaging Orders and Impact on Surgical Wait Times at a Comprehensive Cancer Center. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S428-34.
Variation in Additional Breast Imaging Orders and Impact on Surgical Wait Times at a Comprehensive Cancer Center.
Golshan M, Losk K, Mallory MA, Camuso K, Cutone L, Caterson S, Bunnell CA
Implementation of a Breast/Reconstruction Surgery Coordinator to Reduce Preoperative Delays for Patients Undergoing Mastectomy With Immediate Reconstruction. J Oncol Pract. 2016 Mar; 12(3):e338-43.
Implementation of a Breast/Reconstruction Surgery Coordinator to Reduce Preoperative Delays for Patients Undergoing Mastectomy With Immediate Reconstruction.
Gross AH, Leib RK, Tonachel A, Tonachel R, Bowers DM, Burnard RA, Rhinehart CA, Valentim R, Bunnell CA
Teamwork and Electronic Health Record Implementation: A Case Study of Preserving Effective Communication and Mutual Trust in a Changing Environment. J Oncol Pract. 2016 11; 12(11):1075-1083.
Teamwork and Electronic Health Record Implementation: A Case Study of Preserving Effective Communication and Mutual Trust in a Changing Environment.
Barroso-Sousa R, Paes FR, Vaz-Luis I, Batista RB, Costa RB, Losk K, Camuso K, Metzger-Filho O, Hughes ME, Bunnell CA, Golshan M, Winer EP, Lin NU
Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. Breast. 2016 Dec; 30:136-140.
Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study.
Fornier MN, Martin M, Klimovsky J, Bunnell CA
Manageable safety profile in patients with taxane-resistant metastatic breast cancer (MBC) treated with ixabepilone: Final report. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10587.
Manageable safety profile in patients with taxane-resistant metastatic breast cancer (MBC) treated with ixabepilone: Final report.
Final efficacy results of a phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10511.
Final efficacy results of a phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline.
Phase I/II trial in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline: Final safety data. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10528.
Phase I/II trial in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline: Final safety data.
Campos SM, Parker L, Chen W, Bunnell CA, Atkinson T, Lee J, Matulonis UA, Harris LN, Krasner CN
Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractory gynecological malignancies or metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5085.
Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractory gynecological malignancies or metastatic breast cancer.
Losk K, Vaz-Luis I, Camuso K, Batista R, Lloyd M, Tukenmez M, Golshan M, Lin NU, Bunnell CA
Factors Associated With Delays in Chemotherapy Initiation Among Patients With Breast Cancer at a Comprehensive Cancer Center. J Natl Compr Canc Netw. 2016 12; 14(12):1519-1526.
Factors Associated With Delays in Chemotherapy Initiation Among Patients With Breast Cancer at a Comprehensive Cancer Center.
Gropper A, Burstein HJ, Harris L, Anderson KS, Gold JM, Younger WJ, Bunnell CA, Najita JS, Winer EP, Mayer EL
Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ breast cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):e11074.
Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ breast cancer.
Kadish S, Haskett C, Sanderson K, Benneyan J, Reilly C, Pedulla LV, Brown L, Camuso K, Bunnell CA
Using real time locating systems (RTLS) to redesign room allocation in an ambulatory cancer care setting. J Clin Oncol. 2014 Oct 20; 32(30_suppl):157.
Using real time locating systems (RTLS) to redesign room allocation in an ambulatory cancer care setting.
Hergrueter CA, Camuso K, Lin NU, Cutone L, Hirshfield-Bartek J, Roberts P, Runkle W, Kadish S, Losk K, Bunnell CA
Standardizing coordination between surgical oncology and reconstructive surgery for breast cancer patients undergoing mastectomy with immediate reconstruction. J Clin Oncol. 2014 Oct 20; 32(30_suppl):110.
Standardizing coordination between surgical oncology and reconstructive surgery for breast cancer patients undergoing mastectomy with immediate reconstruction.
Schleicher S, Baugh C, Bunnell CA, Mersereau R, Potiris S, Jacobson JO
Characteristics of emergency department visits among non-admitted oncology patients. J Clin Oncol. 2014 Oct 20; 32(30_suppl):37.
Characteristics of emergency department visits among non-admitted oncology patients.
Mann S, Kalfin M, Lane S, Weingart S, Bunnell CA
Team training in adult oncology. J Clin Oncol. 2012 Dec; 30(34_suppl):27.
Kadish S, Golshan M, Lin N, Hirshfield-Bartek J, Cutone L, Bunnell CA, Weingart S
Reducing breast cancer chemotherapy treatment delays by improving the transition from surgical to medical oncology. J Clin Oncol. 2013 Nov; 31(31_suppl):51.
Reducing breast cancer chemotherapy treatment delays by improving the transition from surgical to medical oncology.
Mann S, Weingart S, Kalfin M, Norden AD, Buswell LA, Constantine M, Fuller F, Briccetti F, Thiele J, Freter R, Kostka J, Sherwood GK, O'Connor J, Bunnell CA
Disseminating team training across an academic cancer center and community-based satellites. J Clin Oncol. 2013 Nov; 31(31_suppl):188.
Disseminating team training across an academic cancer center and community-based satellites.
Castells MC, Friend DS, Bunnell CA, Hu X, Kraus M, Osteen RT, Austen KF
The Journal of allergy and clinical immunology
The presence of membrane-bound stem cell factor on highly immature nonmetachromatic mast cells in the peripheral blood of a patient with aggressive systemic mastocytosis. J Allergy Clin Immunol. 1996 Oct; 98(4):831-40.
The presence of membrane-bound stem cell factor on highly immature nonmetachromatic mast cells in the peripheral blood of a patient with aggressive systemic mastocytosis.
Frei E, Ara G, Teicher B, Bunnell C, Richardson P, Wheeler C, Tew K, Elias A
Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence. Cancer Chemother Pharmacol. 2000; 45(3):239-46.
Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence.
Quality of life issues among women undergoing high-dose chemotherapy for breast cancer. Breast Dis. 2001; 14:41-50.
Quality of life issues among women undergoing high-dose chemotherapy for breast cancer.
Stearns V, Slack R, Greep N, Henry-Tilman R, Osborne M, Bunnell C, Ullmer L, Gallagher A, Cullen J, Gehan E, Hayes DF, Isaacs C
Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol. 2005 Oct 01; 23(28):6919-30.
Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial.
Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8340-7.
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
Bunnell CA, Thompson L, Buswell L, Berkowitz R, Muto M, Sheets E, Shulman LN
A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. Cancer. 1998 Feb 01; 82(3):561-6.
A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.
Oral 5-FU analogues in the treatment of breast cancer. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):39-43.
Oral 5-FU analogues in the treatment of breast cancer.
Frei E, Richardson P, Avigan D, Bunnell C, Wheeler C, Elias A
The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses. Bone Marrow Transplant. 1999 Nov; 24(9):939-45.
The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses.
Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30.
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
Hanser SB, Bauer-Wu S, Kubicek L, Healey M, Manola J, Hernandez M, Bunnell C
Journal of the Society for Integrative Oncology
Effects of a music therapy intervention on quality of life and distress in women with metastatic breast cancer. J Soc Integr Oncol. 2006; 4(3):116-24.
Effects of a music therapy intervention on quality of life and distress in women with metastatic breast cancer.
Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN
International journal of radiation oncology, biology, physics
Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):496-504.
Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
Thomas E, Tabernero J, Fornier M, Conté P, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Baselga J, Rivera E, Guarneri V, Poulart V, Klimovsky J, Lebwohl D, Martin M
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007 Aug 10; 25(23):3399-406.
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
Losk K, Freedman RA, Lin NU, Golshan M, Pochebit SM, Lester SC, Natsuhara K, Camuso K, King TA, Bunnell CA
Implementation of Surgeon-Initiated Gene Expression Profile Testing (Onco type DX) Among Patients With Early-Stage Breast Cancer to Reduce Delays in Chemotherapy Initiation. J Oncol Pract. 2017 09; 13(9):e815-e820.
Implementation of Surgeon-Initiated Gene Expression Profile Testing (Onco type DX) Among Patients With Early-Stage Breast Cancer to Reduce Delays in Chemotherapy Initiation.
Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003 Jan 01; 21(1):46-53.
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.
Elkin EB, Weinstein MC, Kuntz KM, Bunnell CA, Weeks JC
Adjuvant ovarian suppression versus chemotherapy for premenopausal, hormone-responsive breast cancer: quality of life and efficacy tradeoffs. Breast Cancer Res Treat. 2005 Sep; 93(1):25-34.
Adjuvant ovarian suppression versus chemotherapy for premenopausal, hormone-responsive breast cancer: quality of life and efficacy tradeoffs.
Current perspectives for treatment of breast cancer. Breast Cancer. 2000; 7(4):380-8.
Current perspectives for treatment of breast cancer.
Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003 Aug 01; 21(15):2889-95.
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Rosenberg SM, Ligibel JA, Meyerhardt JA, Jacobsen ED, Garber JE, Nekhlyudov L, Bunnell CA, Nutting P, Sprunck-Harrild K, Walsh SK, Partridge AH
Journal of cancer education : the official journal of the American Association for Cancer Education
Developing a Novel Model to Improve Research and care for Cancer Survivors: a Feasibility Study. J Cancer Educ. 2019 04; 34(2):229-233.
Developing a Novel Model to Improve Research and care for Cancer Survivors: a Feasibility Study.
Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP
Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000 Mar; 18(6):1212-9.
Docetaxel administered on a weekly basis for metastatic breast cancer.
Roché H, Yelle L, Cognetti F, Mauriac L, Bunnell C, Sparano J, Kerbrat P, Delord JP, Vahdat L, Peck R, Lebwohl D, Ezzeddine R, Curé H
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol. 2007 Aug 10; 25(23):3415-20.
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
Will we be able to care for cancer patients in the future? Oncology (Williston Park). 2010 Dec; 24(14):1343-8.
Will we be able to care for cancer patients in the future?
Bunnell CA, Supko JG, Eder JP, Clark JW, Lynch TJ, Kufe DW, Shulman LN
Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies. Cancer Chemother Pharmacol. 2001 Nov; 48(5):347-55.
Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies.
Lumping versus splitting: the splitters take this round. J Clin Oncol. 2002 Sep 01; 20(17):3576-7.
Lumping versus splitting: the splitters take this round.
Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003 Jun 15; 97(12):2972-7.
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.